Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial ...

Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or ...

The No UPCODE Act—with some refinements—is a good start insofar it establishes some key pieces of reform, but a broader ...

Nasdaq-listed AI company gains overwhelming shareholder support for its transformational merger, positioning MBody AI ($CHEK) ...

过去5年，中国医疗体系迎来深刻变革：中国人均预期寿命达到79岁，基本医保覆盖超13亿人，药品价格显著下降，远程医疗几乎实现县域全覆盖。即日起，中国网开设《医在中国Q＆A》系列问答栏目，聚焦医疗变革背后的制度创新，解读中国在分级诊疗、中医药发展、公共卫 ...

Net loss for the third quarter of 2025 was $29.7 million, compared to net income of $4.5 million in the third quarter of 2024. Included in this quarter’s loss was a total of $16.7 million of non-cash ...

A：坚持中国医疗卫生事业的公益性方向，将人民健康置于优先发展的战略地位。基本医疗保险参保率稳定在95％以上。2024年，全国基本医保参保13.27亿人，长期护理保险制度参保1.9亿人，职工和居民住院费用目录内基金支付比例分别稳定在80％和70％。

ENDRA Life Sciences Inc. ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease ("MASLD") and ...